Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis...

Area of Science:

• Biochemistry
• Orthopedics
• Pharmacology

Background:

• Osteoarthritis (OA) involves subchondral bone remodeling due to altered osteoblast metabolism.
• Understanding the effects of chondroitin sulfate (CS) and glucosamine sulfate (GS) on OA bone biomarkers is crucial.

Purpose of the Study:

• To investigate the impact of CS and GS, individually and combined, on osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B ligand (RANKL), and osteoblast resorptive activity in human OA subchondral bone.

Main Methods:

• Human OA subchondral bone osteoblasts were treated with CS, GS, or both, with or without vitamin D3.
• Assessed alkaline phosphatase, osteocalcin, OPG and RANKL expression (mRNA) and production (ELISA).
• Measured osteoblast pro-resorptive activity using co-cultures on a synthetic calcium phosphate thin film.

Main Results:

• CS and GS did not affect alkaline phosphatase or osteocalcin levels.
• CS, and the combination of CS and GS, upregulated OPG expression and production.
• CS and the combination of CS and GS significantly reduced RANKL expression and osteoblast resorptive activity, increasing the OPG/RANKL ratio.

Conclusions:

• CS and GS do not compromise osteoblast integrity or key bone biomarkers.
• CS and the combination of CS and GS positively influence OA subchondral bone by increasing the OPG/RANKL ratio and reducing bone resorption.
• These findings provide mechanistic insights into the therapeutic effects of CS and GS in OA pathophysiology.